13 results
8-K
EX-99.3
INVA
Innoviva Inc
28 Sep 15
Regulation FD Disclosure
12:00am
to tiotropium 18mcg once daily (hazard ratio: 0.62; 95% confidence interval [CI]: 0.54, 0.71; p<0.001) or placebo (hazard ratio: 0.37; 95% CI: 0.30, 0.45
8-K
EX-99.2
INVA
Innoviva Inc
28 Sep 15
Regulation FD Disclosure
12:00am
, hazard ratios).
· UMEC/VI significantly reduced the risk of deteriorations in lung function and SGRQ score in the ITT population versus TIO (Table 3 … )(a)4 unit SGRQ total score increase
HR (95% CI)(a)
Moderate-to-severe COPD exacerbation
HR (95% CI)(a)
*p<0.001; †p=0.045; ‡p=0.004; (a)Hazard
8-K
EX-99.1
INVA
Innoviva Inc
8 Sep 14
Other Events
12:00am
=337; (d)treatment difference (95% CI); (e)n=333; (f)n=338; (g)n=335; (h)n=340; (i)hazard ratio (95% CI); (j)odds ratio (95% CI); BL: baseline
Safety
8-K
EX-99.5
INVA
Innoviva Inc
4 Sep 12
Other Events
12:00am
severe asthma exacerbation (primary endpoint) was significantly delayed with FF/VI vs. FF (hazard ratio [HR] 0.795 [95% CI: 0.642, 0.985]; interim
8-K
EX-99.2
qojm ak53
4 Sep 12
Other Events
12:00am
8-K
EX-99.1
g65twxfzehr3
4 Sep 12
Other Events
12:00am
8-K
EX-99.2
cao6ryp0cw
20 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
fyuicayffr7i 1jwig
20 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
zoxfgppk
14 Jan 10
Regulation FD Disclosure
12:00am
S-1
EX-10.10
hs3k7cgssgc6oji6i3n
21 Mar 00
IPO registration
12:00am
- Prev
- 1
- Next